Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Memorial Sloan Kettering Cancer Center · City Of Hope National Medical Center · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
732
total citations
- FWCI
- 64.84
- Percentile
- 100%
- References
- 34
Citations per year
Authors
20- CHCraig H. MoskowitzCorresponding
Memorial Sloan Kettering Cancer Center
- ANAuayporn Nademanee
City Of Hope National Medical Center
- TMTamás Masszi
Unified Szent István and Szent László Hospital, Stem Cell Institute
- EAEdward Agura
Baylor University Medical Center
- JHJerzy Hołowiecki
The Maria Sklodowska-Curie National Research Institute of Oncology
Topics & keywords
Topics
Keywords
- Medicine
- Brentuximab vedotin
- Autologous stem-cell transplantation
- Transplantation
- Internal medicine
- Clinical endpoint
- Surgery
- Placebo
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.